Tscan Therapeutics, Inc.
Clinical trials sponsored by Tscan Therapeutics, Inc., explained in plain language.
-
Supercharged donor cells aim to stop blood cancer relapse after transplant
Disease control Recruiting nowThis early-phase study tests whether specially engineered donor immune cells (TSC-100 or TSC-101) can safely reduce the risk of cancer returning after a stem cell transplant. About 75 adults with acute myeloid leukemia, myelodysplastic syndromes, or acute lymphoblastic leukemia w…
Phase: PHASE1 • Sponsor: TScan Therapeutics, Inc. • Aim: Disease control
Last updated Jun 18, 2026 11:53 UTC
-
Scientists hunt for immune system targets in autoimmune patients
Knowledge-focused Recruiting nowThis study collects tissue and blood samples from 300 people with autoimmune diseases like Crohn's disease, multiple sclerosis, and celiac disease. Researchers aim to find the specific targets that immune cells (T cells) attack in inflamed tissues. The goal is to discover new tar…
Sponsor: TScan Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 23, 2026 20:33 UTC
-
15-Year watch begins for pioneering T-Cell therapy recipients
Knowledge-focused Recruiting nowThis study monitors up to 1,000 people who previously received an experimental T-cell therapy (TSC-100 or TSC-101) for blood cancers like AML, ALL, or MDS. Researchers will track side effects and survival for 15 years after treatment to understand the therapy's long-term safety a…
Sponsor: TScan Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 18, 2026 11:48 UTC